How should hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system be managed?
This review provides clinical guidance on managing hyperkalemia induced by RAAS inhibitors, particularly in high-risk patients.
Hyperkalemia can develop as a result of treatment with angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers. This side effect is most common in patients with risk factors such as diabetes mellitus, heart failure, chronic kidney disease, or advanced age. This review explains the pathophysiology and offers clinical guidance for management.
Biff F. Palmer (Wed,) studied this question.